摘要
目的探讨盐酸埃克替尼一线治疗晚期非小细胞肺癌的临床效果及对患者免疫功能的影响。方法选取2014年3月—2016年9月秦皇岛市第四医院收治的使用盐酸埃克替尼一线治疗的晚期非小细胞肺癌108例作为研究对象,回顾性分析其临床及随访资料,并对其临床疗效、治疗前后免疫功能、不良反应及治疗后总生存期进行分析评价。结果 (1)108例均未出现因药物相关不良反应而终止治疗者,其中部分缓解49例(45.37%),疾病稳定51例(47.22%),疾病进展8例(7.41%),客观有效率为45.37%,疾病控制率为92.59%。对各基本变量的近期疗效进行统计学分析,结果发现有无脑转移对近期疗效有影响。(2)治疗4周后108例CD3+、CD4+及CD4+/CD8+均较治疗前明显升高,而CD8+较治疗前明显下降,差异具有统计学意义(P<0.05)。(3)108例皮疹发生率74.07%,腹泻发生率50.00%,恶心、呕吐发生率32.41%,食欲下降发生率21.30%,口炎发生率12.96%。(4)随访截止时108例存活率为73.15%,中位总生存期为38个月。结论盐酸埃克替尼一线治疗晚期非小细胞肺癌的临床效果较为突出,并且可以明显提高患者的细胞免疫功能。
Objective To investigate the clinical efficacy of icotinib hydrochloride in first-line treatment of advanced non-small cell lung cancer(NSCLC)and its effect on immune function.Methods A total of 108 patients with advanced NSCLC who were treated with icotinib as first-line treatment in the Fourth Hospital of Qinhuangdao from March 2014 to September 2016 were enrolled as subjects.The clinical data and follow-up data of all patients were analyzed retrospectively.And its clinical efficacy,immune function before and after treatment,adverse effects and overall survival after surgery were analyzed and evaluated.Results ①There were no drug-related adverse effects which led to early termination of the treatment.Among them,49 patients(45.37%)were partially relieved,51(47.22%)had stable condition,and 8(7.41%)experienced disease progression.Therefore,the objective response rate was 45.37%and the disease control rate was 52.78%.A statistical analysis of the short-term efficacy of the basic variables revealed that NSCLC accompanied by brain metastases had an impact on the short-term efficacy.②Four weeks after treatment,the percentage of CD3+,CD4+,and CD4+/CD8+of 108 patients was significantly higher than that before treatment,whereas the percentage of CD8+was significantly lower than that before treatment,showing significant differences(P<0.05).③After treatment,the incidence of rash and diarrhoea in 108 cases was 75.47%and 50.94%respectively,and the incidence of nausea and vomiting,the loss of appetite and stomatitis was 33.02%,21.30%,and 12.96%.④The survival rate at follow-up was 73.15%,and the median overall survival was 38 months.Conclusion The first-line treatment with icotinib hydrochloride is an effective strategy for advanced NSCLC,which can significantly improve the cellular immune function of patients.
作者
田春艳
李馥郁
杨晋
赵月
初桂伟
张宁
TIAN Chun-yan;LI Fu-yu;YANG Jin;ZHAO Yue;CHU Gui-wei;ZHANG Ning(Department of Medical Oncology,the Fourth Hospital of Qinhuangdao,Qinhuangdao,Hebei 066000,China)
出处
《临床误诊误治》
2018年第8期64-68,共5页
Clinical Misdiagnosis & Mistherapy
基金
秦皇岛市科学技术研究与发展计划项目(201602A238)
关键词
癌
非小细胞肺
盐酸埃克替尼
治疗结果
免疫功能
Carcinoma,non-small-cell lung
Iclotriptyline hydrochloride
Treatment outcome
Immune function
